Skip to content

Group News

Financial Mail cover story – 22 June 2017

Jun 26, 2017

Price gouging is not in Aspen’s DNA, says founder Stephen Saad, incensed at the thought that his company would exploit the sick. But Aspen’s predicament, and that of all drug firms, boils down to the tension between a drug company’s perceived responsibility to provide life-saving drugs to patients at a reasonable price, and its natural…


Partnering with the South African Department of Health to Enhance Public Healthcare

Jun 9, 2017

One of Aspen’s key business imperatives is the creation of stakeholder value. The communities Aspen operates within remain amongst the Group’s most important stakeholders, with healthcare being one of the key aspects to ensuring sustainable communities. While South Africa is currently burdened with one of the world’s most disproportionate disease profiles, it also has enthusiastic…


Aspen cleared of alleged anti-competitive behavior by DA

May 29, 2017

Durban – JSE Limited-listed Aspen Pharmacare (APN), a leading pharmaceutical company in the southern hemisphere, has welcomed the statement issued by the Democratic Alliance (“DA”) earlier today in which it has confirmed that it is satisfied that there is no evidence that Aspen has engaged in alleged anti-competitive behavior as per the DA’s statement issued…


Aspen concludes strategic M.O.U with the Russian Federation

May 29, 2017

Windhoek, Namibia – JSE Limited listed Aspen Pharmacare (APN), a leading pharmaceutical company in the southern hemisphere, has announced that a memorandum of understanding (“M.O.U”) has been concluded between Aspen’s Russian business and the Vladivostok Far Eastern Federal University (“F.E.F.U”). The Deputy Prime Minister of Russia Mr. Yury Trutnev, who has delegated authority from the…


Statement in response to The Times of London report on 20 May 2017 on Florinef

May 20, 2017

Having noted the report published in The Times of London on 20 May 2017 titled “Massive price rise for vital drug put pets’ lives at risk”, Aspen wishes to express its disappointment and concern that much of the information and clarification it provided to The Times’ Billy Kenber prior to the report being published has…


Opening of European Commission proceedings

May 15, 2017

Aspen confirms that the European Commission has opened proceedings to investigate certain actions of Aspen Holdings and certain of its European subsidiaries. While Aspen is not currently in a position to comment on these proceedings, it reaffirms its commitment to fair and open competition in markets in the European Union and around the world. Aspen…


Aspen’s response to the reported Competition Commission investigation

Apr 23, 2017

Durban – Media reports that the Competition Commission has decided to take up the Democratic Alliance’s request to investigate the alleged anti-competitive conduct of Aspen Pharmacare (“Aspen”) in South Africa, in its preliminary investigation into the pharmaceutical sector, has reference. Aspen welcomes the process and the opportunity to categorically set aside such allegations of anti-competitive…


Statement in response to press reports of 14 and 15 April 2017

Apr 18, 2017

In reference to the articles reported in the European press on 14 and 15 April 2017, Aspen Pharmacare Holdings Limited (“Aspen”) has the following comments: Aspen has clearly demonstrated its commitment to providing quality medicines affordably over many years. The supply of the oncology products in question is no exception. Aspen’s status as a responsible…


Honouring Ahmed M Kathrada

Mar 30, 2017

This morning we wake up to the news, that one of the country’s foremost leaders, a true son of the African soil, Ahmed Mohammed Kathrada, Uncle Kathy, had departed our world. Uncle Kathy, as he was and will continue to be affectionately known to us at Aspen, was one of our country’s key architects of…


Aspen’s half-year revenue increases 13% to R19.8 billion

Mar 9, 2017

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading pharmaceutical company in the southern hemisphere, has announced favourable results for the six months ended 31 December 2016. Stephen Saad, Aspen Group Chief Executive said, “The Group has transformed into a global multinational organisation focused on therapeutic specialties over the past few years.…

Scroll To Top